Company Profile

Orion Genomics LLC
Profile last edited on: 9/23/19      CAGE: 3C6V6      UEI:

Business Identifier: Molecular diagnostic products: epigenetics research tools. DNA methylation technologies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

20 South Sarah Street
Saint Louis, MO 63108
   (314) 615-6977
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

With a shift in focus since the firm's founding in 1998 when the firm's focus was primarily in developing genomic research tools and oncology diagnostic products for cancer screening and therapy selection, Orion Genomics have developed to provide genomics research services and clinical laboratory services to leading healthcare and agricultural research organizations. Cstomers include biotechnology companies, pharmaceutical and diagnostics companies, agricultural and seed companies, government agencies and crop boards spanning four continents across the globe. Defining themselves as The Second Code Company, Orion Genomics was first established with the objective of expanding the reach and utility of the then nascent genomics technologies. The firm has grown to have established strategic partnerships and collaborations in the US, Europe and Southeast Asia. With three divisions -- Genomics Research and Services, Clinical Research and Services and Orion Biosains -- involves R&D scientists and bioinformaticians from around the world. Teams apply their expertise to develop alternative solutions and creative approaches to challenging issues in various industries such as human health and agriculture. With over 100 patents and patents pending, Orion Genomics has established itself as an innovator in the application and use of genetic and epigenetic technologies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 1 NIH $98,781
Project Title: DNA Methylation-Based Biomarkers of UTI Outcome

Key People / Management

  Nathan D Lakey -- President & Chief Executive Officer

  John Atkinson -- CFO

  Blaire Bacher -- Scientist

  John Finney -- Co-Founder

  Jeffrey A Jeddeloh

  Jorge Leon